The biologically active compound of

Animals Male Mice Anti-Anxiety Agents / administration & dosage Behavior, Animal / drug effects Diazepam / pharmacology Dose-Response Relationship, Drug Ethanol / pharmacology Flumazenil / pharmacology Maze Learning / drug effects Plant Extracts / administration & dosage Reflex, Righting / drug effects Withania / chemistry
Anxiety GABAA receptors Withania somnifera diazepam docosanyl ferulate flumazenil

Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
Oct 2021
Historique:
pubmed: 4 5 2021
medline: 10 2 2022
entrez: 3 5 2021
Statut: ppublish

Résumé

Clinical and experimental studies support the therapeutic potential of This study was designed to assess whether DF (0.05, 0.25 and 2 mg/kg), similarly to diazepam (2 mg/kg), may exert anxiolytic effects, whether these effects may be significantly blocked by the benzodiazepine antagonist flumazenil (10 mg/kg) and whether DF may lack some of the benzodiazepines' typical motor, cognitive and motivational side effects. The behavioural paradigms Elevated Plus Maze, Static Rods, Novel Object Recognition, Place Conditioning and potentiation of ethanol-induced Loss of Righting Reflex were applied on male CD-1 mice. Similarly to diazepam, DF exerts anxiolytic effects that are blocked by flumazenil. Moreover, at the full anxiolytic dose of 2 mg/kg, DF lacks typical benzodiazepine-like side effects on motor and cognitive performances and on place conditioning. Moreover, DF fails to potentiate ethanol's (3 g/kg) depressant activity at the ethanol-induced Loss of Righting Reflex paradigm. These data point to DF as an effective benzodiazepine-like anxiolytic compound that, in light of its lack of motor, mnemonic and motivational side effects, could be a suitable candidate for the treatment of anxiety disorders.

Sections du résumé

BACKGROUND BACKGROUND
Clinical and experimental studies support the therapeutic potential of
AIMS OBJECTIVE
This study was designed to assess whether DF (0.05, 0.25 and 2 mg/kg), similarly to diazepam (2 mg/kg), may exert anxiolytic effects, whether these effects may be significantly blocked by the benzodiazepine antagonist flumazenil (10 mg/kg) and whether DF may lack some of the benzodiazepines' typical motor, cognitive and motivational side effects.
METHODS METHODS
The behavioural paradigms Elevated Plus Maze, Static Rods, Novel Object Recognition, Place Conditioning and potentiation of ethanol-induced Loss of Righting Reflex were applied on male CD-1 mice.
RESULTS RESULTS
Similarly to diazepam, DF exerts anxiolytic effects that are blocked by flumazenil. Moreover, at the full anxiolytic dose of 2 mg/kg, DF lacks typical benzodiazepine-like side effects on motor and cognitive performances and on place conditioning. Moreover, DF fails to potentiate ethanol's (3 g/kg) depressant activity at the ethanol-induced Loss of Righting Reflex paradigm.
CONCLUSIONS CONCLUSIONS
These data point to DF as an effective benzodiazepine-like anxiolytic compound that, in light of its lack of motor, mnemonic and motivational side effects, could be a suitable candidate for the treatment of anxiety disorders.

Identifiants

DOI: 10.1177/02698811211008588 PMID: 33934670
pubmed: 33934670
doi: 10.1177/02698811211008588
doi:

Substances chimiques

Anti-Anxiety Agents 0
Diazepam Q3JTX2Q7TU
Ethanol 3K9958V90M
Flumazenil 40P7XK9392
Plant Extracts 0
docosanyl ferulate 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1277-1284

Auteurs

Riccardo Maccioni (R)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.

Filippo Cottiglia (F)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.

Elias Maccioni (E)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.

Giuseppe Talani (G)

Institute of Neuroscience, National Research Council (C.N.R.), University Campus, Cagliari, Italy.

Enrico Sanna (E)

Institute of Neuroscience, National Research Council (C.N.R.), University Campus, Cagliari, Italy.
Center of Excellence for the Study of Neurobiology of Addiction, University of Cagliari, Cagliari, Italy.

Valentina Bassareo (V)

Center of Excellence for the Study of Neurobiology of Addiction, University of Cagliari, Cagliari, Italy.
Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
ORCID: 0000-0001-9439-6090

Sanjay B Kasture (SB)

Pinnacle Biomedical Research Institute, Bhopal, India.

Elio Acquas (E)

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy.
Center of Excellence for the Study of Neurobiology of Addiction, University of Cagliari, Cagliari, Italy.
ORCID: 0000-0002-4783-9319

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The biologically active compound of
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The biologically active compound of
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Anxiolytiques › The biologically active compound of
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement animal › The biologically active compound of
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzazépines › Benzodiazépines › Benzodiazépinones › Diazépam › The biologically active compound of
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › The biologically active compound of
questionsmedicales.fr › Composés chimiques organiques › Alcools › Éthanol › The biologically active compound of
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzazépines › Benzodiazépines › Benzodiazépinones › Flumazénil › The biologically active compound of
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Apprentissage du labyrinthe › The biologically active compound of
questionsmedicales.fr › Préparations pharmaceutiques › Extraits de plantes › The biologically active compound of
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Réflexe › Réflexe de redressement › The biologically active compound of
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Solanales › Solanaceae › Withania › The biologically active compound of